Shigeru Sato

Shigeru Sato

Auto-generated profile, based on publicly available information

Shigeru Sato

Department of Ophthalmology, The University of Osaka Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2000 in Neurology
Verified
Journal Article
Closed access
PDF file
KYK. Yamakawa
K. Yamakawa
HKHiroshi Kuroda
Hiroshi Kuroda
KFKazuo Fujihara
Kazuo Fujihara
SSS. Sato
S. Sato
INI. Nakashima
I. Nakashima
YIY. Itoyama
Y. Itoyama
Patient 1. Patient 1 was a 67-year-old woman. When she was 62, right-sided blindness developed over 4 days, but the vision was restored in a year. At age 65, she became quadriplegic and felt numb below the neck. After 3 months of rehabilitation, she could walk using a cane. At age 67, she developed bilateral blurred vision, paraplegia, and dysuria subacutely, …

1 December 2020 in Ophthalmology Retina
Verified
Journal Article
Closed access
NSNobuhiko Shiraki
Nobuhiko Shiraki
TWTaku Wakabayashi
Taku Wakabayashi
YIYasushi Ikuno
Yasushi Ikuno
NMNagakazu Matsumura
Nagakazu Matsumura
SSShigeru Sato
Shigeru Sato
KNKohji Nishida
Kohji Nishida

4 August 2022 in Ophthalmology Retina
Verified
Journal Article
Closed access
MKMasanori Kanai
Masanori Kanai
SSSusumu Sakimoto
Susumu Sakimoto
STShizuka Takahashi
Shizuka Takahashi
KNKentaro Nishida
Kentaro Nishida
KMKazuichi Maruyama
Kazuichi Maruyama
KNKohji Nishida
Kohji Nishida

10 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CHChikako Hara
Chikako Hara
MSMasaki Suzue
Masaki Suzue
SFSatoko Fujimoto
Satoko Fujimoto
YFYoko Fukushima
Yoko Fukushima
KSKaori Sayanagi
Kaori Sayanagi
KNKohji Nishida
Kohji Nishida
Background: Recently, faricimab was approved as the new drug for neovascular age-related macular degeneration (nAMD). We lack the knowledge to choose between the existing drug and this new drug to use for treatment-naïve nAMD cases. In this study, we compared the functional and morphologic effects in loading dose between patients with treatment-naïve nAMD treated with either intravitreal aflibercept (IVA) or intravitreal faricimab (IVF) injection in a clinical setting. Method: This retrospective study included 30 eyes of 28 patients who started treatment with IVA between June and September 2022 and 30 eyes of 29 patients who were administered IVF between October 2022 and March 2023. All patients received three monthly IVA or IVF. The best corrected visual acuity (BCVA), central retinal thickness (CRT), and the proportion of eyes with residual exudative change at baseline and 1,2, and 3 months after initial treatment were compared between the groups. Results: The mean BCVA significantly improved from pre-treatment after the loading dose in the IVA group (0.46 ± 0.46–0.36 ± 0.37, p = 0.0047) but not in the IVF group (0.46 ± 0.41–0.44 ± 0.45, p = 0.60). The mean CRT significantly improved in both groups. The proportion of eyes with residual exudative change was greater in the IVF group than in the IVA group 2 months after the first treatment (p = 0.026). The analysis of cases that achieved complete resolution of exudative changes after the loading dose showed that the IVA group had a significant improvement in the BCVA, whereas the IVF group did not (p = 0.0047 and 0.20, respectively). Conclusions: Although both IVA and IVF significantly improved CRT, the BCVA improved significantly in the IVA group but not in the IVF group.

1 April 1997 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
HYHajime Julie Yuasa
Hajime Julie Yuasa
SSShigeru Sato
Shigeru Sato
HYHiroaki Yamamoto
Hiroaki Yamamoto
TTTakashi Takagi
Takashi Takagi
Two distinct cDNAs encoding troponin C (TnC) isoforms were isolated from the ascidian, Halocynthia roretzi One is expressed in adult body wall smooth muscle and heart muscle, and the other in larval striated muscle. The H. rorezti gene is composed of 7 exons separated by 6 introns, and Southern blot analysis showed that TnC is a single copy gene product. The two isoforms of TnC were derived through the alternative splicing of the third exon.

12 March 2019 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
SSShigeru Sato
Shigeru Sato
TMTakeshi Morimoto
Takeshi Morimoto
KHKikuko Hotta
Kikuko Hotta
TFTakashi Fujikado
Takashi Fujikado
KNKohji Nishida
Kohji Nishida
Bardet-Biedl syndrome (BBS), characterized by rod-cone dystrophy, postaxial polydactyly, central obesity, hypogonadism, renal abnormalities, and mental retardation, is a rare autosomal recessive disorder. To date, 21 causative genes have been reported. Here we describe a Japanese BBS patient with a novel compound heterozygous mutation in TTC8. To the best of our knowledge, this is the first description of a BBS patient with a mutation in the TTC8 gene in Japan.